Annabel Goodwin

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina et al. · Annals of Oncology · 2020 · 372 citations · Full text

Fumarate Hydratase–deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings

Wesley J. Harrison, Juliana Andrici, Fiona Maclean et al. · The American Journal of Surgical Pathology · 2015 · 137 citations · Full text

Genetic Testing, Uterine Fibroids, Cancer Pathology +15

Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study

Aung Ko Win, James G. Dowty, Jeanette C. Reece et al. · The Lancet Oncology · 2021 · 112 citations · Full text

Lynch Syndrome, Retrospective Cohort Study, Cancer Risk +10

A recurrent germline <i><scp>BAP1</scp></i> mutation and extension of the <i><scp>BAP1</scp></i> tumor predisposition spectrum to include basal cell carcinoma

Karin Wadt, Lauren G. Aoude, Peter A. Johansson et al. · Clinical Genetics · 2014 · 89 citations

Recurrent Mutation, Cancer Pathology, Pathology +17